MedTrace Logo

Influence of Varenicline on the Antiplatelet Action of Clopidogrel

NCT01308671 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2015-06-24

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of steady-state varenicline on the antiplatelet action of clopidogrel in patients with coronary artery disease.

Conditions

Interventions

DRUG

Varenicline

Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days

BEHAVIORAL

Counseling and psychosocial support

Blank group will receive the same counseling and psychosocial support as varenicline group

Sponsors & Collaborators

  • General Hospital of Chinese Armed Police Forces

    lead OTHER

Principal Investigators

  • Hui Liang Liu, Doctor · Department of Cardiology of General Hospital of Chinese People's Armed Police Forces

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-12-31
Completion
2016-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01308671 on ClinicalTrials.gov